← Eichor
Study identifier: NCT06863974 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

High-throughput Omic Technology for Identification of Biomarkers of Relapsing Acute Disseminated Encephalomyelitis in Immune Cell Network

Condition: Acute Disseminated Encephalomyelitis · Encephalitis Autoimmune  ·  Sponsor: University Hospital, Angers

PhaseNA
Planned participants20
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Acute disseminated encephalomyelitis (ADEM) is a neuroinflammatory disorder of the central nervous system, manifesting itself as impaired consciousness, even to the point of coma, and multifocal neurological deficits. ADEM is the most common encephalitis in children. Moreover, 50-65% of ADEM in children is associated with the presence of anti-MOG antibodies (MOGAD). In fact, ADEM is the most frequent clinical presentation of MOGAD in children, 50-75% before the age of 10. The risk of recurrence is higher in pediatric MOGAD of ADEM manifestation, up to 30%, compared to myelitis or optic neuritis. Multiphasic MOGAD are more frequently associated with sequelae in 50-69% of cases, versus 4-32% for monophasic forms. In ADEM, cognitive and epileptic sequelae predominate. The 2020 European consortium and the 2022 national diagnosis and care protocol recommend the introduction of disease-modifying therapies as early as the second attack of the disease, or in the event of distant sequelae, in order to limit relapses and sequelae. However, these treatments take several months to take effect. There is currently no reliable predictive factor for MOGAD recurrence other than the persistence of an elevated blood anti-MOG antibody level (≥1:1280) at 1 year. The aim of this study is therefore to identify biomarkers associated with MOGAD recurrence from the first attack. To this end, we will study the transcriptome of circulating blood mononuclear cells by single-cell next-generation RNA sequ…

This description comes directly from the study's public registry record.

Talk to the study team

Nail BENALLEGUE, DOCTOR  ·  +33241354445  ·  nail.benallegue@chu-angers.fr

Always discuss trial participation with your own doctor first.

Locations (8)

CHU d'AngersAngers, FranceRecruiting
Univesity Hostipal of BrestBrest, FranceRecruiting
Univesity Hostipal of APHPLe Kremlin-Bicêtre, FranceRecruiting
CHU MontpellierMontpellier, FranceNot Yet Recruiting
Univesity Hostipal of NantesNantes, FranceRecruiting
Hôpital Necker Enfants MaladesParis, FranceNot Yet Recruiting
Univesity Hostipal of RennesRennes, FranceRecruiting
Univesity Hostipal of ToursTours, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06863974